Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.47 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.38 |
| ▸ | GOT1 | P17174 | 1/20 | 0.38 |
| ▸ | KYAT1 | Q16773 | 1/20 | 0.38 |
| ▸ | KYAT3 | Q6YP21 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4563192 | 0.69 | NOTUM (0.42) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL4563191 | 0.68 | NOTUM (0.41) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL9089813 | 0.67 | MTNR1A (0.51) | NOTUM | |
| SCHEMBL9089821 | 0.67 | MTNR1A (0.51) | NOTUM | |
| SCHEMBL10759991 | 0.64 | NOTUM (0.39) | NOTUMARGRM4MEN1KMT2A | |
| SCHEMBL21839107 | 0.64 | NOTUM (1.00) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL29896718 | 0.64 | NOTUM (1.00) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL17382966 | 0.64 | NOTUM (1.00) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL4554098 | 0.64 | NOTUM (1.00) | NOTUMAADATGOT1KYAT1KYAT3 | |
| SCHEMBL30404647 | 0.63 | NOTUM (0.53) | NOTUMAADATGOT1KYAT1KYAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | CSO of MicuRx Pharmaceuticals, Inc. | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157434-A1 | Antimicrobial heterocyclic compounds for treatment of bacterial infections | NISCH, NOD1, NQO1 | NOTUM 2955/4885AADAT 1166/4885GOT1 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.